India's Lupin clears patent hurdle with Astellas Pharma, keeps Mirabegron sales in US

Feb 10 (Reuters) – Indian drugmaker Lupin said on Tuesday it has settled a patent infringement dispute with Japan's Astellas Pharma over the bladder disorder drug Mirabegron, allowing it to continue selling the product in the United States. Under the agreement, Lupin and its U.S. unit will pay Astellas $90 million, including a $75 million upfront payment and per-unit licensing fees on Mirabegron sales through September 2027, the company said in an exchange filing. The settlement resolves Lupin's pending litigation with Astellas and enables the company to continue marketing Mirabegron in the United States. Lupin had previously disclosed the patent dispute with the Japanese drugmaker last April over its generic version of Myrbetriq, Astellas' overactive bladder drug. (Reporting by Surbhi Misra in Bengaluru; Editing by Sherry Jacob-Phillips)

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)